Figure 1



A
Screened n=1740
Not-randomised n=849
Randomised n=891
Baseline efficacy n=890
Safety population n=885
Post-dose efficacy (mITT) n=855
B
Randomised n=891
4mg b.i.d. 357 (40%)
75mg b.i.d. 268 (30%)
125mg b.i.d. 266 (30%)
alone 54
+AChEI/Mem 303
alone 42
+AChEI/Mem 226
alone 40
+AChEI/Mem 226
baseline:
65wk:
34 (63%)
218 (72%)
26 (62%)
146 (65%)
25 (62%)
130 (58%)

Figure 2



A
B
Change in ADAS-cog
Change in ADL
Week
treatment
control
75mg b.i.d. alone
125mg b.i.d. alone
75mg b.i.d. + AChEI/Mem
125mg b.i.d. + AChEI/Mem

Figure 3



A
Change in ADAS-cog
0.0
-2.5
-5.0
-7.5
-10.0
20
40
60
Week
treatment
4mg b.i.d. + AChEI/Mem
4mg b.i.d. alone
B
Change in ADL
0.0
-2.5
-5.0
-7.5
-10.0
20
40
60
Week
treatment
4mg b.i.d. + AChEI/Mem
4mg b.i.d. alone

Figure 4



A
B
Change in LVV
2000
4000
6000
8000
20
40
60
Week
treatment
control
75mg b.i.d. alone
125mg b.i.d. alone
75mg b.i.d. + AChEI/Mem
125mg b.i.d. + AChEI/Mem

Figure 5



A
B
Change in TPV
400
800
1200
1600
20
40
60
Week
treatment
control
75mg b.i.d. alone
125mg b.i.d. alone
75mg b.i.d. + AChEI/Mem
125mg b.i.d. + AChEI/Mem

Figure 6




A
B
Change in HV
-25
-50
-75
-100
-125
20
40
60
Week
treatment
control
75mg b.i.d. alone
125mg b.i.d. alone
75mg b.i.d. + AChEI/Mem
125mg b.i.d. + AChEI/Mem

Figure 7


A
Change in LVV
2000
4000
6000
8000
10000
20
40
60
Week
treatment
4mg b.i.d. + AChEI/Mem
4mg b.i.d. alone
B
Change in TPP
-400
-800
-1200
-1600
-2000
20
40
60
Week
treatment
4mg b.i.d. + AChEI/Mem
4mg b.i.d. alone
C
Change in HV
-25
-50
-75
-100
-125
20
40
60
Week
treatment
4mg b.i.d. + AChEI/Mem
4mg b.i.d. alone